Water

Water

SCHEMBL757242

O.O=C1CCNCC1

nearest known ligand 0.00

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO

The experimentally established mechanism targets of Water. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL70721 0.97
Hydrochloric Acid SCHEMBL5544397 0.97 TRIM24 (0.39)
Bromide SCHEMBL22283857 0.97
Bromide SCHEMBL30521957 0.97 TRIM24 (0.39)
SCHEMBL83334 0.96
SCHEMBL6529739 0.96 TRIM24 (0.44)
Hydrochloric Acid SCHEMBL8498788 0.94 TRIM24 (0.37)
Water SCHEMBL1845123 0.94
SCHEMBL25405068 0.93 HIF1A (0.43)
Fluoride SCHEMBL22283826 0.93

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 197 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118206501-A Preparation method of rumorph 西安远大科创医药科技有限公司 2024-06-18 CN claimed
EP-1260511-B1 Process for the preparation of 5-chloro-1-(4-fluorophenyl)-3-(1,2,3,6-tetrahydropyridin-4-yl)indole and method of manufacturing sertindole LUNDBECK & CO AS H (DK) 2004-12-29 EP claimed
CN-118206501-A Preparation method of rumorph 西安远大科创医药科技有限公司 2024-06-18 CN disclosed
WO-2023101326-A1 NOVEL COMPOUND AS AUTOTAXIN INHIBITOR AND USE THEREOF 주식회사 넥스트젠바이오사이언스 2023-06-08 WO disclosed
EP-3890715-A1 THERAPEUTICS TARGETING MUTANT ADENOMATOUS POLYPOSIS COLI (APC) FOR THE TREATMENT OF CANCER The Board Of Regents Of The University Of Texas System (US) 2021-10-13 EP disclosed
WO-2020117972-A1 THERAPEUTICS TARGETING MUTANT ADENOMATOUS POLYPOSIS COLI (APC) FOR THE TREATMENT OF CANCER THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2020-06-11 WO disclosed
CN-103958468-B Piperidinylnaphthylacetic acids 弗·哈夫曼-拉罗切有限公司 2017-03-01 CN disclosed
CN-103958468-A Piperidinylnaphthylacetic acids HOFFMANN LA ROCHE 2014-07-30 CN disclosed
US-8586748-B2 2-sulfonylamino-4-heteroaryl butyramide antagonists of CCR10 BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-11-19 US disclosed
CN-101646656-B Pyrimidine hydrazide compounds as PGDS inhibitors SANOFI AVENTIS SPA 2013-08-14 CN disclosed
US-8399473-B2 Macrocyclic spiropiperidine beta-secretase inhibitors for the treatment of Alzheimer's disease Merck, Sharp & Dohme, Corp. (US) 2013-03-19 US disclosed
CN-1092071-A Promote spiro piperidines and homologue that tethelin discharges MERCK & CO INC (US) 1994-09-14 CN disclosed
CN-1023320-C Process for preparing a benzoxazinnorifamycim derivative KANEGAFUCHI CHEMICAL IND (JP) 1993-12-29 CN disclosed
US-5114949-A Treating disorders associated with 5HT uptake RHONE-POULENC SANTE (FR) 1992-05-19 US disclosed
CN-1054071-A Oral active renin inhibitors PFIZER (US) 1991-08-28 CN disclosed
EP-0438233-A2 Orally active renin inhibitors PFIZER INC. (US) 1991-07-24 EP disclosed
EP-0022705-B1 DERIVATIVES OF TETRAHYDROPYRIDINYL-INDOL AND THEIR SALTS, THEIR PREPARATION, THEIR APPLICATION AS MEDICINES, AND COMPOSITIONS CONTAINING THEM ROUSSEL-UCLAF (FR) 1983-04-06 EP disclosed
US-4278677-A Tetrahydropyridinyl indoles ROUSSEL UCLAF (FR) 1981-07-14 US disclosed
EP-0022705-A1 Derivatives of tetrahydropyridinyl-indol and their salts, their preparation, their application as medicines, and compositions containing them ROUSSEL-UCLAF (FR) 1981-01-21 EP disclosed
US-4196209-A Treating psychic disorders with piperidyl-indoles ROUSSEL UCLAF (FR) 1980-04-01 US disclosed